Table 1

Evaluation of CWR22R tumors from treatment groups by visual grading and descriptions of CD34 staining and MVD scoring

TreatmentMVDGradeComments
Control412+Branching, thick vessels
rhuVEGF91+Not branching, thin vessels
rhuVEGF/paclitaxel41+Not branching, thin vessels
rhuVEGF + 14 days21Thin vessels
Posttreatment paclitaxel512+Branching, thick vessels